70724-72-0

Basic information

• Product Name: N-PIPERIDIN-4-YLMETHANESULFONAMIDE
• Synonyms: N-Piperidin-4-yl methanesulfoniamide;N-piperidin-4-ylmethanesulfonamide(SALTDATA: 1.15HCl H2O 0.05C1H4O3S1);MFCD13193871;Methanesulfonamide,N-4-piperidinyl-
• CAS NO: 70724-72-0
• Molecular Formula: C₆H₁₄N₂O₂S
• Molecular Weight: 178.25
• Mol File: 70724-72-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 299.392°C at 760 mmHg
• Flash Point: 134.868°C
• Appearance: /
• Density: 1.225g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.515
• PKA: 10.68±0.20(Predicted)
• CAS DataBase Reference: N-PIPERIDIN-4-YLMETHANESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-PIPERIDIN-4-YLMETHANESULFONAMIDE(70724-72-0)
• EPA Substance Registry System: N-PIPERIDIN-4-YLMETHANESULFONAMIDE(70724-72-0)

Safety Data

• Hazardous Substances Data: 70724-72-0(Hazardous Substances Data)

Usage

General Description

N-PIPERIDIN-4-YLMETHANESULFONAMIDE, also known as PPSM, is a chemical compound that has been studied for its potential use in various medical applications. It is a derivative of piperidine and contains a methanesulfonamide group. PPSM has been investigated for its potential pharmacological properties, including its possible use as an antihypertensive and vasodilator agent, as well as its application in the treatment of neurodegenerative diseases. It is also being researched for its potential use as a building block in the synthesis of other compounds with pharmaceutical and biological relevance. Further research is ongoing to explore the full range of potential applications for N-PIPERIDIN-4-YLMETHANESULFONAMIDE.

InChI:InChI=1/C6H14N2O2S/c1-11(9,10)8-6-2-4-7-5-3-6/h6-8H,2-5H2,1H3

Upstream product

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 800401-97-2 tert-butyl 4-(methylsulfonamido)piperidine-1-carboxylate 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 124-63-0 methanesulfonyl chloride 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 68996-25-8 N-(1-Benzylpiperidin-4-yl)methanesulfonamide 

Downstream Products

• 1359969-52-0 2-chloro-4-(3-cyclopentyl-7-(4-(methylsulfonyl)piperazine-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl)benzonitrile 
• 1445902-03-3 N-isobutyl-N-[4-(4-(methylsulfonamido)piperidin-1-yl)benzyl]-1-phenylmethanesulfonamide 
• 1424393-63-4 N-(1-(4-nitrophenyl)piperidin-4-yl)methanesulfonamide 
• 1359969-49-5 N-(1-(2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carbonyl)piperidin-4-yl)methanesulfonamide 
• 1206772-14-6 N-[1-[2-[3-tert-butyl-2-methoxy-5-(2-oxo-1H-pyridin-3-yl)phenyl]ethyl]-4-piperidyl]methanesulfonamide 
• 1131739-16-6 2-(3,4-dichloro-phenyl)-4-(4-methanesulfonylamino-piperidin-1-yl)-2-methyl-butyric acid methyl ester 
• 1131739-21-3 2-(3,4-dichloro-phenyl)-4-(4-methanesulfonylamino-piperidin-1-yl)-butyric acid methyl ester 

Relevant articles and documents

Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4, Cy and n are as presented in the description.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.